JP2023546316A - 多価ｓｔｉｎｇ活性化組成物およびその使用法 - Google Patents

多価ｓｔｉｎｇ活性化組成物およびその使用法 Download PDF

Info

Publication number
JP2023546316A
JP2023546316A JP2023515254A JP2023515254A JP2023546316A JP 2023546316 A JP2023546316 A JP 2023546316A JP 2023515254 A JP2023515254 A JP 2023515254A JP 2023515254 A JP2023515254 A JP 2023515254A JP 2023546316 A JP2023546316 A JP 2023546316A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
sting
composition according
pc7a
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023515254A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546316A5 (https=
Inventor
ジンミン ギャオ
スシン リ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2023546316A publication Critical patent/JP2023546316A/ja
Publication of JP2023546316A5 publication Critical patent/JP2023546316A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/01—Atom Transfer Radical Polymerization [ATRP] or reverse ATRP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023515254A 2020-09-08 2021-09-08 多価ｓｔｉｎｇ活性化組成物およびその使用法 Pending JP2023546316A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063075560P 2020-09-08 2020-09-08
US63/075,560 2020-09-08
PCT/US2021/049365 WO2022055929A1 (en) 2020-09-08 2021-09-08 Polyvalent sting activating compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2023546316A true JP2023546316A (ja) 2023-11-02
JP2023546316A5 JP2023546316A5 (https=) 2024-09-11

Family

ID=80469374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023515254A Pending JP2023546316A (ja) 2020-09-08 2021-09-08 多価ｓｔｉｎｇ活性化組成物およびその使用法

Country Status (11)

Country Link
US (1) US12036319B2 (https=)
EP (1) EP4210707A4 (https=)
JP (1) JP2023546316A (https=)
KR (1) KR20230066019A (https=)
CN (1) CN116490193A (https=)
AU (1) AU2021340623A1 (https=)
BR (1) BR112023004271A2 (https=)
CA (1) CA3191593A1 (https=)
IL (1) IL301190A (https=)
MX (1) MX2023002797A (https=)
WO (1) WO2022055929A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805309A (zh) * 2022-06-07 2022-07-29 中国药科大学 苯并杂环类化合物及其制备方法、药物组合物和应用
CN117599199B (zh) * 2023-11-20 2025-03-04 北京大学 用于靶蛋白水解的聚合物及其制备方法和用途
CN120242033B (zh) * 2025-06-03 2025-08-22 合肥市第一人民医院 一种纳米组装体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511483A (ja) * 2016-03-02 2019-04-25 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 免疫療法のためのｓｔｉｎｇ活性化ナノワクチン
US20200078312A1 (en) * 2018-09-07 2020-03-12 Wisconsin Alumni Research Foundation Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment
JP2022536993A (ja) * 2019-06-22 2022-08-22 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 生分解性超ｐＨ感受性ポリマー

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
US20180344758A1 (en) 2014-12-17 2018-12-06 Lipogen Llc Method of Treating Cancer with cGAMP or cGAsMP
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
EP3691640A1 (en) * 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Methods for administering sting agonists
WO2019161171A1 (en) 2018-02-16 2019-08-22 Sperovie Biosciences, Inc. Nanoparticle formulations of sting agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511483A (ja) * 2016-03-02 2019-04-25 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 免疫療法のためのｓｔｉｎｇ活性化ナノワクチン
US20200078312A1 (en) * 2018-09-07 2020-03-12 Wisconsin Alumni Research Foundation Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment
JP2022536993A (ja) * 2019-06-22 2022-08-22 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 生分解性超ｐＨ感受性ポリマー

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. IMMUNOL., vol. 199(11), JPN6025040924, 2017, pages 3840 - 3848, ISSN: 0005700315 *
MED. RES. REV., vol. 40, JPN6025040923, December 2019 (2019-12-01), pages 1117 - 1141, ISSN: 0005700316 *

Also Published As

Publication number Publication date
CA3191593A1 (en) 2022-03-17
CN116490193A (zh) 2023-07-25
IL301190A (en) 2023-05-01
BR112023004271A2 (pt) 2023-04-04
AU2021340623A1 (en) 2023-04-13
WO2022055929A1 (en) 2022-03-17
EP4210707A4 (en) 2024-10-16
MX2023002797A (es) 2023-05-04
US20220071903A1 (en) 2022-03-10
KR20230066019A (ko) 2023-05-12
EP4210707A1 (en) 2023-07-19
US12036319B2 (en) 2024-07-16

Similar Documents

Publication Publication Date Title
US12036319B2 (en) Polyvalent sting activating compositions and uses thereof
CN113660957A (zh) 包含抗体-tlr激动剂缀合物的组合物、方法和用途
JP2010526091A (ja) 癌の処置のための生物学的な標的基の改変
JP2019522028A (ja) 核酸送達用の崩壊性細胞透過性複合体
JP2010526091A5 (https=)
JP7811545B2 (ja) ｐＨ応答性ブロックコポリマー組成物、ミセル、及び使用の方法
WO2017044803A1 (en) Expression vector delivery system and use thereof for inducing an immune response
US20240277854A1 (en) Immolative cell-penetrating complexes for nucleic acid delivery to the lung
JP2020517599A (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
KR20230097142A (ko) 치료용 pH 반응성 조성물
HK40094751A (zh) 多价sting激活组合物及其用途
CN115461357A (zh) 用于递送药物活性剂的组合物和方法
US20120165268A1 (en) P53 fusion proteins and methods of making and using thereof
HK40092555A (zh) 治疗性ph响应性组合物
HK40077764B (zh) Ph响应性嵌段共聚物组合物、胶束和使用方法
JP2025532958A (ja) ＥｐｈＡ２結合保留ペプチド及びそれを含む組成物
HK40096444A (zh) 抗体-tlr激动剂缀合物、方法及其用途
HK40062074A (en) Compositions containing, methods and uses of antibody-tlr agonist conjugates

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260402